When: Clean close above $153.91 on volume >8M

Then: Upgrade to Hold/Overweight — breakout becomes thesis upgrade, not new entry

When: Post-Q3 print with Yeztugo >$1.1B with persistence sustained AND HIV franchise intact AND deleveraging progress

Then: Upgrade path to Overweight

Deep trim to 25-35% of benchmark OR full exit; re-enter post-catalyst on clarified setup

• Current price $148 with structural stop at $133.26 implies $14.83 downside versus $3.42 upside to resistance = 4.3-to-1 downside-to-upside ratio
• Aggressive analyst's 50-70% trim still leaves $7 to $9 million mark-to-market exposure on gap-down scenario to $130-$133 zone
• Conservative analyst proposes 25-35% trim as minimum, or full exit with defined re-entry framework post-catalyst
• GILD is a defensive, low-beta (0.336), dividend-paying, cash-generative pharma held for capital preservation
• Binary catalysts produce disorderly price action; stop-based risk management fails in catalyst-driven tape
• FDA verdict is August 27 (one trading day away) with symmetric outcome risk
• 10 EMA at $144.13 is only $3.96 below current price; gap through invalidates trailing stop before reaction
• If FDA unfavorable, stock could gap through $141 to June lows around $120-$125
• Balance sheet absorbed 33% increase in net debt plus $20 billion-plus cumulative impairment history
• Macro does not support multiple expansion with 87% probability of zero Fed cuts

→ vs aggressive: 50-70% trim is insufficient; $148 stock at 50-70% of benchmark into binary FDA event still leaves $7-9M mark-to-market exposure on 10-12% gap down to $130-$133 zone

→ vs aggressive: The 3-to-1 risk-reward re-entry thesis at $141-$144 assumes orderly price action; binary catalysts don't deliver orderly price action and stock could gap through to $120-$125

→ vs aggressive: Aggressive framing of 'optimization' and 'front-running volatility crush' is behavioral finance self-rationalization for continued risk-taking

→ vs neutral: Trailing stop framework fails in catalyst-driven tape; 10 EMA stop at $144.13 is only $3.96 below price and gap down on FDA disappointment invalidates it before reaction

Moderate staged trim to 65-75% of benchmark weight with 25-30% core position maintained; sell one tranche now at 148, defer second tranche to FDA outcome or technical break; define explicit re-entry triggers post-catalyst

• Moderate trim to 65-75% of benchmark weight recommended; neither full exit (conservative) nor 50-70% trim (aggressive) is appropriate
• Stage the trim rather than executing all at once; sell one tranche now at 148, defer second tranche to FDA outcome or technical break
• Maintain a 25-30% core position of benchmark weight to preserve dividend stream, low-beta defensive profile, and positive catalyst upside participation
• Explicit post-catalyst re-entry triggers: scale back toward benchmark weight if stock tags 141-133 zone on FDA disappointment; let core position run if stock gaps above 155 on positive outcome
• Operating income remains 2.54 billion quarterly; free cash flow remains 3.43 billion quarterly; Net Debt to EBITDA at 1.6 times is comfortable for investment-grade pharma
• HIV franchise growing 10% year-over-year; total shareholder yield is 5.4%
• August 25 high came on 4.63 million shares and August 26 on 5.25 million shares, both below the 6.5 million average
• VWMA still rising at 140.64; declining volume into resistance could be consolidation before breakout, not just distribution
• HIV PrEP decision on lenacapavir twice-yearly dosing is paradigm-shifting catalyst that could gap stock 5-8% on approval
• Q2 GAAP loss is non-cash impairment charge, not operating deterioration; headline-driven selling should be avoided
• Current sizing is wrong given catalyst one trading day away with declining volume on new highs and deteriorating balance sheet

→ vs aggressive: The 50-70% trim is not aggressive capital redeployment; it literally follows the technical plan's moderate response recommendation, making it the consensus baseline rather than alpha generation

→ vs aggressive: The risk-reward reload plan only works if the FDA catalyst disappoints; if lenacapavir is approved and stock gaps 5-8% to 155-160, the analyst is left trying to re-enter at higher levels with partial position

→ vs aggressive: The volume distribution argument treats a bearish interpretation as the only valid read; declining volume into resistance could be a coiled spring before breakout rather than distribution

→ vs conservative: The prescription of full exit or 25-35% trim imports momentum-trading rules into a defensive holding; for low-beta, 5.4% yield, dividend-paying pharma, measured de-risking preserves the strategic portfolio role

→ vs conservative: Operating income of 2.54 billion quarterly and free cash flow of 3.43 billion quarterly have not deteriorated; Net Debt to EBITDA at 1.6 times is comfortable; the setup has deteriorated technically but not fundamentally

→ vs conservative: The dismissal of trailing stops as unmanaged overnight gap risk is too binary; options overlays, put spreads, or collars can define downside while preserving upside participation